• Je něco špatně v tomto záznamu ?

A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen

B. Kubickova, JA. Schenk, F. Ramm, K. Markuškienė, J. Reetz, P. Dremsek, PL. Tamosiunas, L. Cepulyte, HA. Trinh, J. Scholz, H. Memczak, M. Hovestädt, R. Ryll, R. Petraityte-Burneikiene, VM. Corman, A. Andersson, D. Becher, MH. Groschup, S....

. 2021 ; 105 (12) : 4957-4973. [pub] 20210615

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018481

Grantová podpora
1322-686 Bundesinstitut für Risikobewertung
ZMVI1-2516-AUK-701 / BMG: 321-4471-02/157 Bundesministerium für Gesundheit
TTU "Emerging Infections" DZIF

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1999-12-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Springer Nature OA/Free Journals od 1975-03-01

Odkazy

PubMed 34129082
DOI 10.1007/s00253-021-11342-7
Knihovny.cz E-zdroje

To generate a hepatitis E virus (HEV) genotype 3 (HEV-3)-specific monoclonal antibody (mAb), the Escherichia coli-expressed carboxy-terminal part of its capsid protein was used to immunise BALB/c mice. The immunisation resulted in the induction of HEV-specific antibodies of high titre. The mAb G117-AA4 of IgG1 isotype was obtained showing a strong reactivity with the homologous E. coli, but also yeast-expressed capsid protein of HEV-3. The mAb strongly cross-reacted with ratHEV capsid protein derivatives produced in both expression systems and weaker with an E. coli-expressed batHEV capsid protein fragment. In addition, the mAb reacted with capsid protein derivatives of genotypes HEV-2 and HEV-4 and common vole hepatitis E virus (cvHEV), produced by the cell-free synthesis in Chinese hamster ovary (CHO) and Spodoptera frugiperda (Sf21) cell lysates. Western blot and line blot reactivity of the mAb with capsid protein derivatives of HEV-1 to HEV-4, cvHEV, ratHEV and batHEV suggested a linear epitope. Use of truncated derivatives of ratHEV capsid protein in ELISA, Western blot, and a Pepscan analysis allowed to map the epitope within a partially surface-exposed region with the amino acid sequence LYTSV. The mAb was also shown to bind to human patient-derived HEV-3 from infected cell culture and to hare HEV-3 and camel HEV-7 capsid proteins from transfected cells by immunofluorescence assay. The novel mAb may serve as a useful tool for further investigations on the pathogenesis of HEV infections and might be used for diagnostic purposes. KEY POINTS: • The antibody showed cross-reactivity with capsid proteins of different hepeviruses. • The linear epitope of the antibody was mapped in a partially surface-exposed region. • The antibody detected native HEV-3 antigen in infected mammalian cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018481
003      
CZ-PrNML
005      
20210830100101.0
007      
ta
008      
210728s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00253-021-11342-7 $2 doi
035    __
$a (PubMed)34129082
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kubickova, Barbara $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany $u RECETOX, Faculty of Science, Masaryk University, 62500, Brno, Czech Republic
245    12
$a A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen / $c B. Kubickova, JA. Schenk, F. Ramm, K. Markuškienė, J. Reetz, P. Dremsek, PL. Tamosiunas, L. Cepulyte, HA. Trinh, J. Scholz, H. Memczak, M. Hovestädt, R. Ryll, R. Petraityte-Burneikiene, VM. Corman, A. Andersson, D. Becher, MH. Groschup, S. Kubick, F. Sellrie, R. Johne, RG. Ulrich
520    9_
$a To generate a hepatitis E virus (HEV) genotype 3 (HEV-3)-specific monoclonal antibody (mAb), the Escherichia coli-expressed carboxy-terminal part of its capsid protein was used to immunise BALB/c mice. The immunisation resulted in the induction of HEV-specific antibodies of high titre. The mAb G117-AA4 of IgG1 isotype was obtained showing a strong reactivity with the homologous E. coli, but also yeast-expressed capsid protein of HEV-3. The mAb strongly cross-reacted with ratHEV capsid protein derivatives produced in both expression systems and weaker with an E. coli-expressed batHEV capsid protein fragment. In addition, the mAb reacted with capsid protein derivatives of genotypes HEV-2 and HEV-4 and common vole hepatitis E virus (cvHEV), produced by the cell-free synthesis in Chinese hamster ovary (CHO) and Spodoptera frugiperda (Sf21) cell lysates. Western blot and line blot reactivity of the mAb with capsid protein derivatives of HEV-1 to HEV-4, cvHEV, ratHEV and batHEV suggested a linear epitope. Use of truncated derivatives of ratHEV capsid protein in ELISA, Western blot, and a Pepscan analysis allowed to map the epitope within a partially surface-exposed region with the amino acid sequence LYTSV. The mAb was also shown to bind to human patient-derived HEV-3 from infected cell culture and to hare HEV-3 and camel HEV-7 capsid proteins from transfected cells by immunofluorescence assay. The novel mAb may serve as a useful tool for further investigations on the pathogenesis of HEV infections and might be used for diagnostic purposes. KEY POINTS: • The antibody showed cross-reactivity with capsid proteins of different hepeviruses. • The linear epitope of the antibody was mapped in a partially surface-exposed region. • The antibody detected native HEV-3 antigen in infected mammalian cells.
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a CHO buňky $7 D016466
650    _2
$a kapsida $7 D002213
650    _2
$a virové plášťové proteiny $7 D036022
650    _2
$a křečci praví $7 D006224
650    _2
$a Cricetulus $7 D003412
650    _2
$a Escherichia coli $7 D004926
650    12
$a virus hepatitidy E $7 D016752
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schenk, Jörg A $u Hybrotec GmbH, 14476, Potsdam, Germany $u UP Transfer GmbH an der Universität Potsdam, 14469, Potsdam, Germany
700    1_
$a Ramm, Franziska $u Branch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany $u Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195, Berlin, Germany
700    1_
$a Markuškienė, Kornelija $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany $u Institute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania
700    1_
$a Reetz, Jochen $u German Federal Institute for Risk Assessment, 10589, Berlin, Germany
700    1_
$a Dremsek, Paul $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany $u Zentrum für Pathobiochemie und Genetik, Medizinische Universität Wien, 1090, Wien, Austria
700    1_
$a Tamosiunas, Paulius Lukas $u Institute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania
700    1_
$a Cepulyte, Laima $u Institute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania
700    1_
$a Trinh, Hoai Anh $u Branch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany
700    1_
$a Scholz, Johannes $u German Federal Institute for Risk Assessment, 10589, Berlin, Germany
700    1_
$a Memczak, Henry $u qpa bioanalytics GmbH, 10585, Berlin, Germany
700    1_
$a Hovestädt, Marc $u qpa bioanalytics GmbH, 10585, Berlin, Germany $u Surflay Nanotec, 12489, Berlin, Germany
700    1_
$a Ryll, René $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany
700    1_
$a Petraityte-Burneikiene, Rasa $u Institute of Biotechnology, Life Sciences Centre, Vilnius University, 02241, Vilnius, Lithuania
700    1_
$a Corman, Victor M $u Institute of Virology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany $u Site Berlin, German Center for Infection Research (DZIF), 10117, Berlin, Germany
700    1_
$a Andersson, Anika $u UP Transfer GmbH an der Universität Potsdam, 14469, Potsdam, Germany $u Branch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany
700    1_
$a Becher, Dietmar $u Micromun GmbH, 17489, Greifswald, Germany
700    1_
$a Groschup, Martin H $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany $u Partner site Hamburg-Lübeck-Borstel-Riems, German Center for Infection Research (DZIF), 17493, Greifswald-Insel Riems, Germany
700    1_
$a Kubick, Stefan $u Branch Bioanalytics and Bioprocesses (IZI-BB), Fraunhofer Institute for Cell Therapy and Immunology (IZI), 14476, Potsdam, Germany $u Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195, Berlin, Germany $u Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus-Senftenberg, the Brandenburg Medical School Theodor Fontane and the University of Potsdam, Potsdam, Germany
700    1_
$a Sellrie, Frank $u Hybrotec GmbH, 14476, Potsdam, Germany $u UP Transfer GmbH an der Universität Potsdam, 14469, Potsdam, Germany
700    1_
$a Johne, Reimar $u German Federal Institute for Risk Assessment, 10589, Berlin, Germany
700    1_
$a Ulrich, Rainer G $u Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 17493, Greifswald-Insel Riems, Germany. rainer.ulrich@fli.de $u Partner site Hamburg-Lübeck-Borstel-Riems, German Center for Infection Research (DZIF), 17493, Greifswald-Insel Riems, Germany. rainer.ulrich@fli.de
773    0_
$w MED00000493 $t Applied microbiology and biotechnology $x 1432-0614 $g Roč. 105, č. 12 (2021), s. 4957-4973
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34129082 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100102 $b ABA008
999    __
$a ok $b bmc $g 1689551 $s 1138927
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 105 $c 12 $d 4957-4973 $e 20210615 $i 1432-0614 $m Applied microbiology and biotechnology $n Appl Microbiol Biotechnol $x MED00000493
GRA    __
$a 1322-686 $p Bundesinstitut für Risikobewertung
GRA    __
$a ZMVI1-2516-AUK-701 / BMG: 321-4471-02/157 $p Bundesministerium für Gesundheit
GRA    __
$a TTU "Emerging Infections" $p DZIF
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace